Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zai Lab Ltd ADR (ZLAB)

Zai Lab Ltd ADR (ZLAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,211,269
  • Shares Outstanding, K 111,963
  • Annual Sales, $ 398,990 K
  • Annual Income, $ -257,100 K
  • EBIT $ -228 M
  • EBITDA $ -220 M
  • 60-Month Beta 0.87
  • Price/Sales 5.48
  • Price/Cash Flow N/A
  • Price/Book 2.87

Options Overview Details

View History
  • Implied Volatility 96.06% (+4.37%)
  • Historical Volatility 38.45%
  • IV Percentile 98%
  • IV Rank 89.52%
  • IV High 102.27% on 04/10/25
  • IV Low 43.03% on 06/11/25
  • Expected Move (DTE 15) 1.95 (9.76%)
  • Put/Call Vol Ratio 1.50
  • Today's Volume 5
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 7,583
  • Open Int (30-Day) 7,751
  • Expected Range 18.00 to 21.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +52.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.40 +2.82%
on 12/02/25
25.63 -22.16%
on 11/05/25
-5.94 (-22.94%)
since 11/04/25
3-Month
19.40 +2.82%
on 12/02/25
34.72 -42.54%
on 10/02/25
-10.05 (-33.50%)
since 09/04/25
52-Week
19.40 +2.82%
on 12/02/25
44.34 -55.01%
on 06/12/25
-8.36 (-29.53%)
since 12/04/24

Most Recent Stories

More News
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 19.95 (+1.01%)
GTBP : 0.6298 (+3.59%)
ROIV : 21.18 (+2.32%)
CCCC : 2.59 (-7.83%)
BMY : 51.95 (+1.94%)
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation...

ZLAB : 19.95 (+1.01%)
Zai Lab Announces Participation in Investor Conferences in November and December 2025

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025: ...

ZLAB : 19.95 (+1.01%)
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with baseline brain metastases...

ZLAB : 19.95 (+1.01%)
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

- Company to host conference call and webcast on November 6, 2025, at 8:00 a.m. ET (9:00 p.m. HKT)

ZLAB : 19.95 (+1.01%)
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (formerly called ZL-1310) as a promising next-generation, first- and best-in-class, Delta-like ligand (DLL3)-targeted...

ZLAB : 19.95 (+1.01%)
Zai Lab Limited (ZLAB) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - September 10, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Zai Lab Limited ("Zai Lab Limited") (NASDAQ: ZLAB) concerning possible...

ZLAB : 19.95 (+1.01%)
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands

Equity Insider News Commentary

ONCY : 0.9807 (+8.19%)
GH : 108.52 (+2.42%)
CLRB : 3.80 (+2.98%)
NEO : 12.17 (+0.41%)
ZLAB : 19.95 (+1.01%)
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands

/CNW/ -- Cancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain...

ONCY : 0.9807 (+8.19%)
GH : 108.52 (+2.42%)
CLRB : 3.80 (+2.98%)
NEO : 12.17 (+0.41%)
ZLAB : 19.95 (+1.01%)
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent...

ZLAB : 19.95 (+1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China....

See More

Key Turning Points

3rd Resistance Point 20.57
2nd Resistance Point 20.39
1st Resistance Point 20.17
Last Price 19.95
1st Support Level 19.77
2nd Support Level 19.59
3rd Support Level 19.37

See More

52-Week High 44.34
Fibonacci 61.8% 34.81
Fibonacci 50% 31.87
Fibonacci 38.2% 28.93
Last Price 19.95
52-Week Low 19.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar